B. Wulf

发表

Cystic fibrosis: the impact of analytical technology for genotype-phenotype studies.

T. Dörk, B. Tümmler, T. Neumann, 1993, Clinica chimica acta; international journal of clinical chemistry.

The Relation of Some Antigenic Determinants of Immunoglobulin G to the Non‐L Chain Portion of the Fab Fragment

H. Deicher, R. Wolf, B. Wulf, 1968 .

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

C. Trautwein, G. Gerken, A. Tran, 2010 .

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

C. Trautwein, G. Gerken, A. Lohse, 2010 .

Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis

B. Tümmler, T. Neumann, U. Wulbrand, 1993, The Lancet.

Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients

T. Dörk, B. Tümmler, T. Neumann, 1994, Human Genetics.

Intra- and extragenic marker haplotypes of CFTR mutations in cystic fibrosis families

K. Klinger, L. Tsui, B. Kerem, 1992, Human Genetics.

Frequency of the F508 deletion in the CFTR gene in Turkish cystic fibrosis patients

B. Tümmler, S. Bremer, J. Reiss, 1990, Human Genetics.

Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene

T. Dörk, B. Tümmler, T. Neumann, 1991, Human Genetics.

Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations

T. Dörk, B. Tümmler, T. Neumann, 2004, Human Genetics.